⌕
BioAge Labs · BIOA · Nasdaq
Tenet 74 · Solid
Compare
$5.10−2.30%At closeTenet 74 · Solid
$5.10−0.12 (−2.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

BioAge Labs (BIOA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is BIOA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 16, 2026 · 14:13 ET
BioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 Transcript

BioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 Transcript…

BIOA −2.3% todayRead at source ↗
● Defense WorldNov 14, 2026 · 03:49 ET
Sol-Gel Technologies (NASDAQ:SLGL) vs. BioAge Labs (NASDAQ:BIOA) Critical Contrast

Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and BioAge Labs (NASDAQ: BIOA - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based o…

BIOA −2.3% todayRead at source ↗
● GlobeNewsWireNov 11, 2026 · 08:00 ETCOMPANY'S OWN WORDS
BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic d…

BIOA −2.3% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 18:46 ET
BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates

BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.56 per share a year ago.…

BIOA −2.3% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 16:30 ETCOMPANY'S OWN WORDS
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027…

BIOA −2.3% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 11:06 ET
Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline

BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

BIOA −2.3% todayRead at source ↗
● Defense WorldOct 22, 2026 · 02:45 ET
BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical Comparison

BioAge Labs (NASDAQ: BIOA - Get Free Report) and Royalty Pharma (NASDAQ: RPRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength …

BIOA −2.3% todayRead at source ↗
● GlobeNewsWireOct 14, 2026 · 08:00 ET
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target

Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep Origin's virtual scree…

BIOA −2.3% todayRead at source ↗
● Defense WorldSep 28, 2026 · 03:23 ET
Bank of America Corp DE Buys 257,855 Shares of BioAge Labs, Inc. $BIOA

Bank of America Corp DE acquired a new position in shares of BioAge Labs, Inc. (NASDAQ: BIOA) in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).…

BIOA −2.3% todayRead at source ↗
● GlobeNewsWireSep 25, 2026 · 16:30 ETCOMPANY'S OWN WORDS
BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic dise…

BIOA −2.3% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 16:01 ET
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

BIOA −2.3% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 14:17 ET
BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

BIOA −2.3% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 08:00 ETCOMPANY'S OWN WORDS
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline re…

BIOA −2.3% todayRead at source ↗
● Seeking AlphaSep 5, 2026 · 08:53 ET
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off

BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% IL-1β suppression and…

BIOA −2.3% todayRead at source ↗
● GlobeNewsWireSep 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic dise…

BIOA −2.3% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just BIOA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.